United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Being able to take an at-home antiviral would be a "game changer," according to Bourla

Pfizer CEO Says Antiviral Pill To Treat Covid Could Be Ready By End Of The Year

The company in March began an early-stage clinical trial testing a new antiviral therapy for Covid.

Pfizer's new at-home pill to treat Covid could be available by end of the year, CEO hopes

BioNTech SE

It could even hint that more big deals could be on the way.

Pfizer and BioNTech About to Sign the Biggest Vaccine Supply Deal Ever: Why It's Great News for Investors

AstraZeneca

U.S. Trade Representative Katherine Tai on Monday met virtually with top executives of drugmakers Pfizer and AstraZeneca PLC to discuss a proposed waiver of certain intellectual property rights in response to the COVID-19 pandemic.

Top U.S. trade negotiator meets Pfizer, AstraZeneca execs on COVID-19 IP waiver

Blackstone Group

Chevron

Disney

CarMax

Public Storage

While most investors use blue-chip stocks to add stability to their portfolio, they make great economic indicators for everyone to watch. The post 7 Blue-Chip Stocks Everyone Should Watch appeared first on InvestorPlace.

7 Blue-Chip Stocks Everyone Should Watch

Adobe

Walgreens

Adobe Inc. on Monday said it has inked deals with Pfizer Inc. , Walgreens Boots Alliance Inc. , Mercy Health, and others in healthcare to leverage Adobe Experience Cloud to transform their customer operations. The companies made the announcement at the annual Adobe Summit conference.

Adobe inks cloud deals with Pfizer, Walgreens, other healthcare companies

Costco

Intel

Texas Instruments

Walmart

We provide a summary of upcoming ex-dividend dates. A summary table with relevant data and key statistics is presented. The table includes the next payout and pay date.

Upcoming Ex-Dividend Dates: April 27-May 10, 2021

AbbVie

Verizon

A small amount of money can get you some big dividends with these three stocks.

The Best Dividend Stocks to Buy With $300 Right Now

Gritstone Oncology Inc

Regeneron Pharmaceuticals

3 Top Coronavirus Stocks to Buy Right Now

Researchers found that 21 days after a single dose of either the Oxford-AstraZeneca or the Pfizer-BioNTech vaccine, new Covid-19 infections had fallen by 65%.

Single dose of Pfizer-BioNTech or Oxford-AstraZeneca vaccine reduces infection rate by 65%, study finds

Pfizer and its German partner BioNTech currently produce one of the most sought-after Covid-19 vaccines. Below are some of the recent updates relating to the shot.

Pfizer Covid-19 Vaccine Updates: Booster Shots, E.U. Supplies

Moderna

Money and pipelines are the two most important factors in picking the most likely to succeed.

The Biggest mRNA Winner: Pfizer, BioNTech, Moderna, or an Under-the-Radar Biotech?

Pfizer Inc. (PFE) Management Presents at 2021 Annual Meeting of Shareholders (Transcript)

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent second-quarter 2021 dividend on the company's common stock, payable June 4, 2021, to holders of the Common Stock of record at the close of business on May 7, 2021. The second-quarter 2021 cash dividend will be the 330th consecutive quarterly dividend paid by Pfizer. The board has decided to maintain Pfizer's quarterly dividend at its current rate despite the planned declaration of a

Pfizer Declares Second-Quarter 2021 Dividend

Can Pfizer's COVID Vaccine Beat the South African Variant?

AstraZeneca's pain is resulting in a big gain for Pfizer and BioNTech.

Pfizer and BioNTech Vaccine Sales Jump $1.4 Billion Thanks to AstraZeneca's Blunders

Biogen

Johnson & Johnson

Sarepta Therapeutics

Vertex Pharmaceuticals

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important updates about key products.

Key Decisions Coming on Products From Vertex, AstraZeneca and Other Pharmas

The European Commission exercises its option to purchase an additional 100 million doses of Pfizer (PFE)/ BioNTech's COVID-19 vaccine, Comirnaty, for EU member states.

Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU

We should know by the fall if his prediction will become reality.

10 Words From Pfizer's CEO That Could Mean $10 Billion in Higher Vaccine Sales

For some investors, the answer is a resounding "yes."

Should You Buy Pfizer in April?

Pfizer is a lot more than the covid vaccine. PFE stock has strong growth potential and is a great dividend stock for 2021.

There Is More To Pfizer Than The Covid Vaccine

J&J asked Covid vaccine rivals Pfizer and Moderna to join a study looking into the potential risk of blood clots, the Wall Street Journal reported.

J&J asked Pfizer and Moderna to help study blood-clot risks but they declined, report says

People are "likely" to need a third dose of the coronavirus vaccine within 12 months of getting the first two, Pfizer's chief executive has said.

People will likely need to have a third dose of a COVID jab within 12 months, Pfizer boss says

It looks more like the flu virus than the polio virus, he said.

The Wall Street Journal: Pfizer's CEO says people will need COVID-19 vaccination shots every year

Studies are still under way to determine whether additional booster shots are needed to maintain immunity, but Pfizer's CEO calls it "a likely scenario."

News for Pfizer Stock (PFE)